全文获取类型
收费全文 | 232篇 |
免费 | 17篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 24篇 |
基础医学 | 22篇 |
口腔科学 | 5篇 |
临床医学 | 17篇 |
内科学 | 42篇 |
皮肤病学 | 1篇 |
神经病学 | 5篇 |
特种医学 | 71篇 |
外科学 | 18篇 |
综合类 | 11篇 |
预防医学 | 18篇 |
眼科学 | 2篇 |
药学 | 11篇 |
中国医学 | 3篇 |
肿瘤学 | 2篇 |
出版年
2023年 | 2篇 |
2020年 | 6篇 |
2019年 | 2篇 |
2018年 | 2篇 |
2016年 | 1篇 |
2015年 | 7篇 |
2014年 | 3篇 |
2013年 | 6篇 |
2012年 | 9篇 |
2011年 | 6篇 |
2010年 | 11篇 |
2009年 | 13篇 |
2008年 | 6篇 |
2007年 | 2篇 |
2006年 | 4篇 |
2005年 | 4篇 |
2004年 | 6篇 |
2003年 | 6篇 |
2002年 | 1篇 |
2001年 | 1篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1998年 | 10篇 |
1997年 | 9篇 |
1996年 | 15篇 |
1995年 | 11篇 |
1994年 | 11篇 |
1993年 | 10篇 |
1992年 | 5篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 7篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 2篇 |
1982年 | 6篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 5篇 |
1976年 | 9篇 |
1975年 | 4篇 |
排序方式: 共有252条查询结果,搜索用时 62 毫秒
51.
??OBJECTIVE To evaluate retrospectively the clinical application of apatinib in a hospital. METHODS The medical records including apatinib were collected during April 2015 to March 2016. Then, the rationality and safety of drug use were evaluated. RESULTS The 84 patients used apatinib during this time, while 15.48% (15 patients) conformed to the approved indications. The major adverse reactions were gastrointestinal disorders, hypertension, skin disorders and myelosuppression. CONCLUSION Irrational use of apatinib such as off-label use, inadequate usage and dosage exists in clinic. Clinicians should pay close attention to the rationality of apatinib, and clinical pharmacists can improve the safety and effectiveness of therapeutic drugs by taking this as the breakthrough point. 相似文献
52.
53.
54.
55.
56.
57.
SSS Guirado JS Conejo-Mir MA Muñoz JB Wite LR Fernandez-Freire JV Ortíz 《Journal of the European Academy of Dermatology and Venereology》2007,21(1):100-103
BACKGROUND: Sitosterolaemia is a lipid disorder in which plasma plant sterol levels are extremely elevated. Sitosterolaemia is clinically characterized by tuberous and tendon xanthomas, premature vascular disease and arthritis. OBJECTIVE: To report a case of sitosterolaemia diagnosed by cutaneous manifestations and to review this rare disease. METHODS: We report the case of a 60-year-old woman who presented with cutaneous xanthomas, arterial hypertension and polyarthralgias. The patient had had hypercholesterolaemia for many years without reduction of serum cholesterol, despite treatment with fenofibrate. RESULTS: Ezetimibe therapy was started, decreasing sitosterol plasmatic levels and tuberous xanthomas after 3 months of treatment. CONCLUSION: It is important to detect levels of sitosterol in plasma in patients with premature vascular disease, presence of xanthomas, and uncontrolled hypercholesterolaemia. Ezetimibe therapy is effective. 相似文献
58.
59.
The articles in this supplement were developed from a recent pan-European conference entitled 'HIV in Europe 2007: Working together for optimal testing and earlier care', which took place on 26–27 November in Brussels, Belgium. The conference, organized by a multidisciplinary group of experts representing advocacy, clinical and policy areas of the HIV field, was convened in an effort to gain a common understanding on the role of HIV testing and counselling in optimizing diagnosis and the need for earlier care. Key topics discussed at the conference and described in the following articles include: current barriers to HIV testing across Europe, trends in the epidemiology of HIV in the region, problems associated with undiagnosed infection and the psychosocial barriers impacting on testing. The supplement also provides a summary of the World Health Organization's recommendations for HIV testing in Europe and an outline of an indicator disease-guided approach to HIV testing proposed by a committee of experts from the European AIDS Clinical Society (EACS). We hope that consideration of the issues discussed in this supplement will help to shift the HIV field closer towards our ultimate goal: provision of optimal HIV testing and earlier care across the whole of the European region. 相似文献
60.
The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells 总被引:2,自引:6,他引:2
Raelson JV; Nervi C; Rosenauer A; Benedetti L; Monczak Y; Pearson M; Pelicci PG; Miller WH Jr 《Blood》1996,88(8):2826-2832
Acute promyelocytic leukemia (APL) is characterized by the translocation, t(15;17) and the expression of a PML/RAR alpha fusion protein that is diagnostic of the disease. There is evidence that PML/RAR alpha protein acts as a dominant negative inhibitor of normal retinoid receptor function and myeloid differentiation. We now show that the PML/RAR alpha fusion product is directly downregulated in response to retinoic acid (tRA) treatment in the human APL cell line, NB4. tRA treatment induces loss of PML/RAR alpha at the protein level but not at the level of mRNA, as determined by Northern blots, by Western blots, and by ligand binding assays and in binding to RA- responsive DNA elements. We present evidence that this regulation is posttranslational. This evidence suggests that tRA induces synthesis of a protein that selectively degrades PML/RAR alpha. We further show that this loss of PML/ RAR-alpha is not limited to the unique APL cell line. NB4, because PML/RAR alpha protein is selectively downregulated by tRA when expressed in the transfected myeloid cell line U937. The loss of PML/RAR alpha may be directly linked to tRA-induced differentiation, because in a retinoid-resistant subclone of NB4, tRA does not decrease PML/RAR alpha protein expression. In NB4 cells, the specific downregulation of the fusion protein decreases the ratio of PML/RAR alpha to wild-type RAR alpha. Because the ratio of expression of PML/RAR alpha to wild-type RAR alpha and PML may be important in maintaining the dominant negative block of myelocytic differentiation, these data suggest a molecular mechanism for restoration by tRA normal myeloid differentiation in APL cells. 相似文献